Figure 3.
Effects of NKG2D CAR-Expressing Vγ9Vδ2 T Cells in a Human CRC Xenograft Model
(A) Experimental outline for the animal study to examine in vivo killing capacity against intraperitoneal (i.p.) xenografts of human HCT116-Luc colorectal cancer (CRC) cells. NSG mice were i.p. injected with 1 × 107 HCT116-luc cells on day 0. The mice were randomized into different groups (n = 6 per group) before beginning CAR-modified Vγ9Vδ2 T cell (γδ T) treatment on day 7. The treatment was conducted twice a week for 3 weeks, 1 × 107 cells per i.p. injection, using PBS and γδ T cells only as controls. (B) Bioluminescent images prior to treatment (day 7) and following the treatments on days 21 and 35. (C) Tumor burden over time by bioluminescent imaging after the treatment. Each mouse is represented by one line. (D) Kaplan-Meier analysis of survival. Statistical analysis of survival between groups was performed using the log-rank test. ∗p < 0.05; ∗∗∗p < 0.001.